Ironwood Pharmaceuticals IRWD Insider Ownership

NASDAQ IRWD

$3.55 -0.08 (-2.20%)

At close: Oct 21, 2026 · 4:00 PM EDT

Insider Holdings by Owner

8.47Mn Shares

Insider Ownership Statistics

as of 30 Sep, 2026

Insider Ownership

10.60%

▲+0.023% pp QoQ

Shares Held by Insiders

17.42Mn

filed for Sep 2026

▲+0.22% QoQ

Shares Outstanding

164.41Mn

164,405,000 shares

Direct Holdings

8.23Mn

Indirect: 9.19Mn

Net Shares Traded (QoQ)

+37.84K

net buying in Sep 2026

Insiders Holding Shares

with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding

Latest —

Average ownership —

Peak ownership —

Shares Purchased/Sold by Insiders

Bought Sold

Latest quarter —

Net over range —

Buying quarters —

Insider Ownership Summary

Updated Oct 5, 2026

Over the trailing 12 months, IRWD insiders sold $22.62 million worth of shares (7.26Mn shares) in open-market trades, with no open-market purchases.

Counted by insider, open-market selling of IRWD stock in the past 12 months came from 8 insiders, with no insider buying.
Alexander J. Denner (Director) was IRWD's largest open-market seller in the past 12 months, with $20.53 million of sales (6.73Mn shares); the latest was on March 17, 2026.
The newest open-market trade among Ironwood Pharmaceuticals insiders came on July 7, 2026, when Ronald Silver (PFO & PAO) made a sale of 127.89K shares for $578,063.
Away from the open market, IRWD insiders received 952.29K shares in stock awards over the last 12 months.
According to Business Quant data, insiders at Ironwood Pharmaceuticals reported 17.28Mn shares in total in their latest Form 4 filings, or 10.51% of the 164.41Mn shares outstanding; that total is down 0.58% from 17.39Mn shares at the end of Q2 2026 and down 21.21% from 21.94Mn shares at the end of Q3 2025.
Indirect holdings, through trusts, partnerships, family members and other entities, make up 53.16% (9.19Mn shares) of Ironwood Pharmaceuticals' insider total, with the other 46.84% (8.1Mn shares) held directly.
The insider holdings in Ironwood Pharmaceuticals belong to 17 insiders who have reported on Form 4 within the past two years.
Ironwood Pharmaceuticals' top three insider holders by shares held are Alexander J. Denner (Director, 9.52Mn shares), Thomas A. McCourt (Chief Executive Officer, 1.9Mn shares) and Michael Shetzline (SVP, CMO, Head Resdrug, 1.18Mn shares).
Alexander J. Denner alone accounts for 55.06% of the shares held by Ironwood Pharmaceuticals insiders.
Over the past 12 months, 14 insiders reported transactions in Ironwood Pharmaceuticals stock in 27 Form 4 filings.
Insider figures for IRWD include Form 4 filings through September 17, 2026.

Form 4 Holdings

Insiders Holding IRWD

Insiders 18

Shares held 8.47Mn

Of outstanding 5.15%

#	Insider	Position	Direct	Total	Share of Insiders	Last Filed
1	Thomas A Mccourt	Chief Executive Officer	1,898,838	1,898,838	22.4%	12 Mar, 2026
2	Michael Shetzline	Svp, Cmo, Head Resdrug	1,179,462	1,179,462	13.9%	12 Mar, 2026
3	Ronald Silver	Pfo Pao	755,250	755,250	8.9%	08 Jul, 2026
4	Mark G Currie	Chief Scientific Officer	676,900	676,900	8.0%	17 Jun, 2026
5	Minardo John	Chief Legal Officer	500,498	500,498	5.9%	12 Mar, 2026
6	Jason Rickard	Svp, Chief Operating Officer	376,316	376,316	4.4%	10 Mar, 2023
7	Tammi L Gaskins	Chief Commercial Officer	350,350	350,350	4.1%	12 Mar, 2026
8	Alexander J Denner	Director	327,549	327,549	3.9%	17 Sep, 2026
9	Sravan Kumar Emany	Svp, Coo And Cfo	309,572	309,572	3.7%	20 Nov, 2024
10	Gregory S. Martini	Chief Financial Officer	297,213	297,213	3.5%	12 Mar, 2026
11	Andrew Davis	Svp, Chief Business Officer	284,685	284,685	3.4%	20 Nov, 2024
12	Jon R Duane	Director	253,820	253,820	3.0%	17 Jun, 2026
13	Julie Mchugh	Director	250,749	250,749	3.0%	17 Jun, 2026
14	Jay Shepard	Director	235,036	235,036	2.8%	17 Jun, 2026
15	Marla L Kessler	Director	229,364	229,364	2.7%	17 Jun, 2026
16	Andrew Dreyfus	Director	228,313	228,313	2.7%	12 Jun, 2025
17	Catherine Moukheibir	Director	181,425	181,425	2.1%	17 Jun, 2026
18	Jeffrey Silber	Svp, Cmo, Head Resdrug	137,036	137,036	1.6%	22 Jul, 2026

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

1,349 Insider Transactions

Source SEC Form 4

Latest quarter Sep 2026

Date	Insider	Position	Transaction	Shares	Price	Value	Shares Held After	Ownership
15 Sep, 2026	Alexander J Denner	Director	Acquired A	3,694	$0.00	$0	327,549	Direct
20 Jul, 2026	Jeffrey Silber	Svp, Cmo, Head Resdrug	Acquired A	137,036	$0.00	$0	137,036	Direct
07 Jul, 2026	Ronald Silver	Pfo Pao	Disposed S	127,890	$4.52	$578.06K	313,680	Direct
16 Jun, 2026	Julie Mchugh	Director	Acquired A	63,481	$0.00	$0	272,320	Direct
16 Jun, 2026	Marla L Kessler	Director	Acquired A	63,481	$0.00	$0	229,364	Direct
16 Jun, 2026	Catherine Moukheibir	Director	Acquired A	63,481	$0.00	$0	181,425	Direct
16 Jun, 2026	Jay Shepard	Director	Acquired A	63,481	$0.00	$0	235,036	Direct
15 Jun, 2026	Alexander J Denner	Director	Acquired A	4,065	$0.00	$0	260,374	Direct
16 Jun, 2026	Mark G Currie	Director	Acquired A	63,481	$0.00	$0	676,900	Direct
16 Jun, 2026	Jon R Duane	Director	Acquired A	63,481	$0.00	$0	253,820	Direct
16 Jun, 2026	Alexander J Denner	Director	Acquired A	63,481	$0.00	$0	323,855	Direct
16 Jun, 2026	Julie Mchugh	Director	Disposed S	21,571	$3.73	$80.46K	250,749	Direct
19 May, 2026	Ronald Silver	Pfo Pao	Acquired A	25,000	$0.00	$0	441,570	Direct
13 Mar, 2026	Alexander J Denner	Director	Acquired A	4,451	$0.00	$0	256,309	Direct
17 Mar, 2026	Alexander J Denner	Director	Disposed S	6,725,000	$3.05	$20.51Mn	9,194,435	Indirect
17 Mar, 2026	Alexander J Denner	Director	Disposed S	5,800	$3.31	$19.20K	9,188,635	Indirect
10 Mar, 2026	Minardo John	Chief Legal Officer	Acquired A	136,612	$0.00	$0	500,498	Direct
10 Mar, 2026	Ronald Silver	Principal Accounting Officer	Acquired A	163,934	$0.00	$0	416,570	Direct
10 Mar, 2026	Gregory S. Martini	Chief Financial Officer	Acquired A	136,612	$0.00	$0	297,213	Direct
10 Mar, 2026	Michael Shetzline	Svp, Cmo, Head Resdrug	Acquired A	136,612	$0.00	$0	658,037	Direct

Showing 1 to 20 of 1,349 transactions